An observational study based on U.S. data compared hazard ratios for death based on overall, unhealthy, and healthy low-carb diet scores according to percentage of energy obtained from total and subtypes of carbohydrate, protein, and fat.
Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
This month's quiz asks readers to evaluate a patient with type 2 diabetes who reports intermittent hypoglycemia. Medications are metformin, insulin glargine, insulin lispro, and atorvastatin. Laboratory studies show a HbA1c level of 8.5%.
One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
Two articles in the May ACP Internist focused on patients with type 2 diabetes—a cover story explained why and how internists should consider patients' drug costs and the latest Pearls from I.M. Peers talked about basal insulin.
Researchers used data from the National Health and Nutrition Examination Survey to determine the body mass index and age thresholds for diabetes screening in major racial/ethnic minority populations.